Evidence map›Paper›PMID 41280534›Full record

ArticleHeart rhythm O22025

Effectiveness of cardiac device envelopes in preventing infections among pacemaker patients: The REINFORCE Brady real-world project.

Matteo Ziacchi, Michele di Silvestro, Procolo Marchese, Francesco Solimene, Vincenzo Paolo Caccavo, Gabriele Zanotto, Giuseppe Boriani, Antonio Dello Russo, Giuseppe Speziale, Marco Barbanti and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Matteo ZiacchiInstitute of Cardiology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Michele di SilvestroDivision of Cardiology, Umberto I Hospital, ASP 4, Enna, Italy.
Procolo MarcheseEP Unit, AST Ascoli Piceno, Ascoli Piceno, Italy.
Francesco SolimeneCasa di Salute Montevergine, Mercogliano, Italy.
Vincenzo Paolo CaccavoOspedale F. Miulli, Acquaviva delle Fonti, Italy.
Gabriele ZanottoOspedale Mater Salutis di Legnago, Legnago, Italy.
Giuseppe BorianiCardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
Antonio Dello RussoAzienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Giuseppe SpezialeCardiac Surgery Department, Santa Maria Hospital, GVM Care & Research, Bari, Italy; Electrophysiology Department, San Carlo di Nancy, GVM Care & Research, Roma, Italy.
Marco BarbantiDivision of Cardiology, Umberto I Hospital, ASP 4, Enna, Italy.
Carlotta FornasiniInstitute of Cardiology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Mauro BiffiInstitute of Cardiology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Saverio IacopinoElectrophysiology Department, Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Infections related to cardiac implantable electrical devices are among the most challenging and costly complications. Although the absorbable antibiotic-eluting envelope has shown efficacy in reducing infection risk, data on its use in pacemaker (PM) and cardiac resynchronization therapy PM (CRT-P) devices are limited. Objectives: This study aimed to assess the effectiveness of the TYRX envelope in preventing systemic and pocket infections in patients undergoing PM or CRT-P implantation or revision. Methods: This retrospective, multicenter analysis included 896 patients undergoing PM or CRT-P implantation or revision between August 2020 and April 2024. Patients were categorized into 2 groups: the envelope group (n = 350), receiving the TYRX envelope, and the control group (n = 546). Results: Over a mean follow-up of 2.2 ± 2.1 years, systemic or pocket infections occurred in 1.2% of patients, with significantly fewer infections in the envelope group (0.3%) than the control group (1.8%) ( Conclusions: In patients with PMs and CRT-Ps, the use of the TYRX envelope is associated with significantly lower occurrence of device-related infections. This benefit was sustained over long-term follow-up, supporting its effectiveness in routine clinical practice.

Indexed as

Antibiotic-eluting envelopeDevice-related complicationsPacemakerPocket infectionSystemic infection

Identifiers

PMID41280534
PMCPMC12635718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.